发展硼中子俘获治疗癌症治疗中心及提供肿瘤免疫细胞治疗服务为集团主要业务活动之一。董事会相信，与该医院合作(包括共同成立广州金沙洲硼中子俘获治疗中心)将会在硼中子俘获治疗方面产生协同效应，深化有关合作，因此有利于集团核心业务长远发展，提升集团地位，并增强其在大湾区影响力，长远可为公司及其股东带来最大回报。On September 19, 2024, Ch Biotech Ser announced that on September 19, 2024, Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd. ("Pengbo (Hainan)") (a wholly-owned subsidiary of the company), its main business is to provide boron neutron capture therapy (BNCT), and Guangzhou University of Traditional Chinese Medicine Jinsa Island Hospital ("the hospital") signed a framework agreement of intent for cooperation, the content is related to boron neutron capture therapy drugs and medical equipment, referral cooperation, equity cooperation, indication expansion, etc.
The hospital is a large non-profit public welfare tertiary comprehensive hospital approved by the Guangzhou Health Commission, integrating medical care, teaching, research, and prevention. It is a major livelihood project in Guangzhou, a 120 emergency network hospital in Guangzhou, one of the first batch of internet hospitals in Guangdong Province, a designated hospital for medical insurance/work-related injury/maternity insurance in Guangzhou, and a hospital linked to public medical care. Hospital, Guangdong Province's off-site and inter-provincial medical insurance direct settlement designated hospital.
The hospital has obtained the National Medical Products Administration (NMPA) Drug Clinical Trial Institution (GCP) qualification and is a master's degree/cultivation base of Guangzhou University of Traditional Chinese Medicine, the chairman unit of Guangzhou Anti-Cancer Association (GACA), and the deputy director unit of the Chinese Society of Clinical Oncology (CSCO). , Director Unit of the Chinese Ethnic Health Association Radiosurgery Training Base, and the first Chairman Unit of the Radiotherapy Branch of the Chinese Medical Doctor Association.
Developing boron neutron capture therapy cancer treatment centers and providing tumor immunotherapy services is one of the group's main business activities. The board of directors believes that cooperating with the hospital (including jointly establishing the Guangzhou Jinsa Island Boron Neutron Capture Therapy Center) will produce synergistic effects in boron neutron capture therapy, deepen cooperation, and therefore benefit the long-term development of the group's core business, enhance the group's status, and strengthen its influence in the Greater Bay Area, which will bring the greatest return to the company and its shareholders in the long run.
